In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Serelaxin fails to meet primary endpoints in phase 3 RELAX-AHF-2 trial

Heart Failure (HF)


Paris, France – 29 April 2017: Serelaxin has failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late breaking results presented for the first time today at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure.1

“This was a huge disappointment as we had such encouraging data from previous studies,” said co-principal investigator (PI) Professor John R. Teerlink, professor of medicine, University of California, San Francisco (UCSF), US.

Acute heart failure (AHF) is the leading cause of hospitalisation in patients 65 years of age and older. Within six months of discharge, up to 15% of patients die and 30–50% are readmitted. Therapy for AHF has essentially been unchanged since the 1970s.

Serelaxin is recombinant human relaxin-2, a hormone with vasodilatory and end-organ protective effects. It is naturally present in all humans, with higher concentrations in pregnant women to prepare for the extra cardiovascular and renal stresses of pregnancy.

In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day five in patients admitted for AHF (p=0.007), a result driven almost exclusively by an improvement in worsening heart failure. Compared to placebo, serelaxin also reduced worsening heart failure by 47% through day five and both all-cause and cardiovascular mortality by 37% through day 180.2

RELAX-AHF-2 was a multicentre trial enrolling approximately 6 600 patients hospitalised for AHF. Patients were randomised within 16 hours from presentation to 48-hour intravenous infusions of serelaxin (30 µg/kg/day) or placebo, both in addition to standard of care. The independently powered primary endpoints were 180-day cardiovascular death and worsening heart failure through day five.

RELAX-AHF-2 did not meet either of its primary endpoints. There was no difference in cardiovascular mortality at 180 days and the trend for a reduction of worsening heart failure through day five with serelaxin was not statistically significant.

There was no beneficial effect on the secondary endpoints of all-cause mortality at 180 days, length of initial hospital stay or the combined endpoint of cardiovascular death or rehospitalisations due to heart/renal failure through day 180. There were no significant safety concerns with serelaxin.

“In RELAX-AHF-2 we continued to show that serelaxin was safe but unfortunately we did not find that it was also efficacious,” said co-PI Professor Marco Metra, Professor of Cardiology, University of Brescia, Italy. “It is concerning that the findings of this trial should be so disparate from the prior RELAX-AHF trial.”

Professor Teerlink said: “These are truly late breaking results and we are still analysing the data to understand these disparate findings. Were we mislead by the results from the moderate number of events in RELAX-AHF or is there still a group of patients in RELAX-AHF-2 who benefitted from serelaxin? Unfortunately for now we’re left with our currently inadequate therapy for AHF.”

In the same session, late breaking results will be presented from the TRUE-AHF trial of the vasodilator ularitide.3 The findings highlight the importance of adhering to eligibility criteria when enrolling patients into a trial.

TRUE-AHF randomised 2 157 patients with AHF to continuous intravenous infusion of ularitide (15 ng/kg/min) or placebo for 48 hours. There was no difference in the risk of cardiovascular death up to 34 months between the two groups despite the drug exerting the expected physiological effects.4

Patients were identified before the trial blind was broken as having been eligible or ineligible for the trial based on whether or not they met the prespecified entry criteria. This revealed that 17% of patients in the trial had been ineligible, largely because of prohibited intravenous medications.

Today’s presentation shows that ularitide significantly improved dyspnoea (shortness of breath) in the 83% of patients who had been eligible for the trial. In contrast, in the 17% of patients blindly identified as having been ineligible, ularitide had a significantly adverse effect on dyspnoea.

Dr Milton Packer, trial PI and Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center, Dallas, Texas, US, said: “What is absolutely amazing is that the drug was statistically significantly better in eligible patients and statistically significantly worse than placebo in ineligible patients. So not only did the two groups respond differently, they responded in opposite directions. The eligibility criteria not only identified the patients who would respond but also identified the patients who would not be harmed.”

He continued: “When you put the eligible and ineligible patients together you get a neutral result. Ineligible patients were being treated with confounding medications which made the interpretation of the data very difficult and took away from the safety of the drug. If the trial’s eligibility criteria had been followed it is likely that we would have found a benefit of ularitide on shortness of breath.”

Dr Packer concluded: “This shows how it is possible for a drug to actually work but a trial not to find it. The rules outlined in a trial design matter and need to be followed, otherwise we might miss a true effect. It’s like ignoring an architect’s plans and then wondering why the house doesn’t work and doesn’t look good.”

ENDS



Notes to editor

ESC Press Office
Tel: +33 (0) 4 89 87 34 83
Email: press@escardio.org

DISCLOSURES
RELAX-AHF-2: Professor Teerlink received research grants, consulting fees and non-financial compensation from Novartis. Professor Metra received consulting honoraria from Amgen, Astra Zeneca, Novartis, Servier, Relypsa, and Trevena.
TRUE-AHF: Cardiorentis.

References and notes
1Professor Metra and Professor Teerlink will present the abstract ‘Serelaxin in acute heart failure’ during the session Late Breaking Trials I: Focus on acute heart failure which takes place on 29 April from 08:30 to 10:00 in room MONET.
2Teerlink JR, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.
3Dr Packer will present the abstract ‘The effects of ularitide on the clinical course and cardiovascular mortality in acutely decompensated heart failure depend on the eligibility of patients for the trial: Deep-dive results of the TRUE-AHF Trial’ during the session Late Breaking Trials I: Focus on acute heart failure which takes place on 29 April from 08:30 to 10:00 in room MONET. He will also discuss the trial during the session How the results of recent randomized clinical trials will impact our practice which takes place on 30 April from 14:15 to 15:45 in room HUGO.
4Packer M, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine. April 12, 2017. DOI: 10.1056/NEJMoa1601895

About Heart Failure 2017 and the 4th World Congress on Acute Heart Failure
Heart Failure is the annual congress of the Heart Failure Association of the ESC. The 4th World Congress on Acute Heart Failure is part of the main programme of Heart Failure 2017.

About the Heart Failure Association
The Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists attending Heart Failure 2017
Heart Failure 2017 takes place 29 April to 2 May in Paris, France at the Palais des Congrès. The full scientific programme is available here

Free registration applies to press representatives. Get accredited and register: here